See the DrugPatentWatch profile for ozempic

Ozempic, also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes. It works by mimicking the functions of natural GLP-1 hormones in the body, which help regulate blood sugar levels [1].

In terms of daily carbohydrate metabolism, Ozempic affects the way the body processes carbohydrates in several ways:

1. Slowing down digestion: Ozempic slows down the rate at which the stomach empties after eating, which leads to a more gradual absorption of glucose into the bloodstream [2]. This helps prevent spikes in blood sugar levels that typically occur after meals.

2. Increasing insulin secretion: Ozempic stimulates the pancreas to produce and release more insulin, a hormone that helps cells absorb glucose from the bloodstream [3]. This results in lower blood sugar levels.

3. Decreasing glucagon secretion: Ozempic also decreases the release of glucagon, a hormone that raises blood sugar levels by prompting the liver to release stored glucose [3]. By reducing glucagon secretion, Ozempic helps maintain lower blood sugar levels.

4. Enhancing satiety: Ozempic has been shown to increase feelings of fullness and reduce appetite, which can lead to a decrease in overall carbohydrate intake [4]. This can further contribute to improved glycemic control.

In summary, Ozempic affects daily carbohydrate metabolism by slowing down digestion, increasing insulin secretion, decreasing glucagon secretion, and enhancing satiety. These effects help regulate blood sugar levels and improve glycemic control in adults with type 2 diabetes.

Sources:
[1] FDA. (2017). Highlights of Prescribing Information: Ozempic (semaglutide) injection. Retrieved from <https://www.fda.gov/media/108141/download>
[2] Drugs.com. (2021). Ozempic. Retrieved from <https://www.drugs.com/ozempic.html>
[3] National Institute of Diabetes and Digestive and Kidney Diseases. (2016). Insulin, Medicines, & Other Diabetes Treatments. Retrieved from <https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes/insulin-medicines-other-diabetes-treatments>
[4] Davies, M., Bergenstal, R. M., Buse, J. B., et al. (2018). Efficacy and Safety of Once-Weekly Semaglutide in Type 2 Diabetes: A Randomised, Placebo-Controlled Trial. The Lancet, 391(10136), 1215-1227. doi: 10.1016/s0140-6736(18)30232-2. Retrieved from <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30232-2/fulltext>
[5] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - Patent Expiration & Drug Sales Data. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>